Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 334

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 334
---
Item 1. Financial Statements

IMMUNEERING CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2025December 31, 2024AssetsCurrent assets:Cash and cash equivalents$227,563,077 $36,144,720 Prepaids and other current assets1,538,752 3,442,849 Total current assets229,101,829 39,587,569 Property and equipment, net892,553 1,122,865 Goodwill6,690,431 6,690,431 Intangible asset, net328,463 350,413 Right-of-use assets3,411,693 3,667,352 Other assets631,297 1,295,783 Total assets$241,056,266 $52,714,413 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$1,600,274 $1,958,536 Accrued expenses7,483,142 4,973,129 Other liabilities80,089 233,665 Lease liabilities381,760 338,438 Total current liabilities9,545,265 7,503,768 Long-term liabilities:Lease liabilities, net of current portion3,534,569 3,824,419 Total liabilities13,079,834 11,328,187 Commitments and contingencies (Note 10)Stockholders’ equity:Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; 0 shares issued or outstanding at September 30, 2025 and December 31, 2024— — Class A common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2025 and December 31, 2024; 63,483,397 and 31,050,448 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively63,483 31,050 Class B common stock, $0.001 par value, 20,000,000 shares authorized at September 30, 2025 and December 31, 2024; 0 shares issued and outstanding at September 30, 2025 and December 31,